Surgery and survival outcomes of 30 patients with neurological deficit due to clear cell renal cell carcinoma spinal metastases

被引:19
作者
Han, Shuai [1 ]
Wang, Ting [1 ]
Jiang, Dongjie [1 ]
Yu, Yang [2 ]
Wang, Yu [1 ]
Yan, Wangjun [1 ]
Xu, Wei [1 ]
Cheng, Ming [1 ]
Zhou, Wang [1 ]
Xiao, Jianru [1 ]
机构
[1] Second Mil Med Univ, Changzheng Hosp, Spine Tumor Ctr, Dept Bone Tumor Surg, Shanghai, Peoples R China
[2] Weifang Peoples Hosp, Dept Dent, Weifang, Shandong, Peoples R China
关键词
Retrospective study; Renal cell carcinoma (RCC); Spinal metastases; Nephrectomy; Surgery; Prognostic factors; SURGICAL-MANAGEMENT; CORD COMPRESSION; BISPHOSPHONATES; PROGNOSIS; ONCOLOGY; CANCER; RADIOTHERAPY; RADIATION; TOKUHASHI; THERAPY;
D O I
10.1007/s00586-015-3912-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The aim of this study was to provide some useful insights into the clinical and imaging presentations, treatment and prognostic factors in patients with neurological deficit caused by clear cell renal cell carcinoma (CCRCC) spinal metastases for the sake of designing individualized therapeutic plans for such patients. A total of 30 patients with neurological deficit due to CCRCC spinal metastases who received surgery in our department were identified during an 8-year period from 2003 to 2012 and used for discussion of treatment options for CCRCC spinal metastases on the basis of literature review and our own experience. Univariate analysis showed that age (a parts per thousand currency sign45 years/> 45 years), visceral metastasis, Tomita score (3-5/6-8), Tokuhashi score (4-9/10-12) and radiotherapy were suggested as the potential prognostic factors. However, the multivariate Cox regression model showed that only Tokuhashi score was an independent prognostic factor. Tokuhashi score 10 or more is a favorable prognostic factor of CCRCC spinal metastasis.
引用
收藏
页码:1786 / 1791
页数:6
相关论文
共 32 条
[1]   Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study [J].
Bhatia, Shailender ;
Curti, Brendan ;
Ernstoff, Marc S. ;
Gordon, Michael ;
Heath, Elisabeth I. ;
Miller, Wilson H., Jr. ;
Puzanov, Igor ;
Quinn, David I. ;
Flaig, Thomas W. ;
VanVeldhuizen, Peter ;
Byrnes-Blake, Kelly ;
Freeman, Jeremy A. ;
Bittner, Rachel ;
Hunder, Naomi ;
Souza, Sonia ;
Thompson, John A. .
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2014, 2
[2]  
Chen Fengshi, 2008, Interact Cardiovasc Thorac Surg, V7, P825, DOI 10.1510/icvts.2008.181065
[3]   Bisphosphonates in oncology [J].
Coleman, Robert E. ;
McCloskey, Eugene V. .
BONE, 2011, 49 (01) :71-76
[4]   Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial [J].
Escudier, B. ;
Michaelson, M. D. ;
Motzer, R. J. ;
Hutson, T. E. ;
Clark, J. I. ;
Lim, H. Y. ;
Porfiri, E. ;
Zalewski, P. ;
Kannourakis, G. ;
Staehler, M. ;
Tarazi, J. ;
Rosbrook, B. ;
Cisar, L. ;
Hariharan, S. ;
Kim, S. ;
Rini, B. I. .
BRITISH JOURNAL OF CANCER, 2014, 110 (12) :2821-2828
[5]   THE USE OF RADIATION IN THE MANAGEMENT OF SPINAL METASTASES [J].
FAUL, CM ;
FLICKINGER, JC .
JOURNAL OF NEURO-ONCOLOGY, 1995, 23 (02) :149-161
[6]   Stereotactic radiosurgery for spinal metastases from renal cell carcinoma [J].
Gerszten, PC ;
Burton, SA ;
Ozhasoglu, C ;
Vogel, WJ ;
Welch, WC ;
Baar, J ;
Friedland, DM .
JOURNAL OF NEUROSURGERY-SPINE, 2005, 3 (04) :288-295
[7]  
Giehl JP, 1999, ANTICANCER RES, V19, P1619
[8]  
HALPERIN EC, 1983, CANCER-AM CANCER SOC, V51, P614, DOI 10.1002/1097-0142(19830215)51:4<614::AID-CNCR2820510411>3.0.CO
[9]  
2-J
[10]   Update on systemic therapies of metastatic renal cell carcinoma [J].
Herrmann, E. ;
Bierer, S. ;
Wuelfing, C. .
WORLD JOURNAL OF UROLOGY, 2010, 28 (03) :303-309